Harel Insurance Investments & Financial Services Ltd. Sells 4,593 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)


Share on StockTwits

Harel Insurance Investments & Financial Services Ltd. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 52.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,164 shares of the biopharmaceutical company’s stock after selling 4,593 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Gilead Sciences were worth $899,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Dodge & Cox increased its stake in Gilead Sciences by 35.7% during the 4th quarter. Dodge & Cox now owns 17,107,888 shares of the biopharmaceutical company’s stock worth $996,706,000 after acquiring an additional 4,500,035 shares during the period. Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter valued at $767,548,000. UBS Asset Management Americas Inc. increased its stake in shares of Gilead Sciences by 4.6% in the 4th quarter. UBS Asset Management Americas Inc. now owns 8,997,053 shares of the biopharmaceutical company’s stock valued at $524,168,000 after purchasing an additional 392,859 shares during the last quarter. Morgan Stanley increased its stake in shares of Gilead Sciences by 18.4% in the 4th quarter. Morgan Stanley now owns 7,124,342 shares of the biopharmaceutical company’s stock valued at $415,063,000 after purchasing an additional 1,106,826 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Gilead Sciences by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 6,534,485 shares of the biopharmaceutical company’s stock valued at $380,700,000 after purchasing an additional 18,926 shares during the last quarter. Hedge funds and other institutional investors own 76.36% of the company’s stock.

In related news, EVP Brett A. Pletcher sold 1,975 shares of the business’s stock in a transaction dated Wednesday, February 10th. The stock was sold at an average price of $67.41, for a total value of $133,134.75. Following the completion of the sale, the executive vice president now directly owns 28,832 shares of the company’s stock, valued at approximately $1,943,565.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brett A. Pletcher sold 1,486 shares of the business’s stock in a transaction dated Thursday, March 11th. The shares were sold at an average price of $63.36, for a total value of $94,152.96. Following the completion of the sale, the executive vice president now directly owns 29,166 shares of the company’s stock, valued at $1,847,957.76. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

Several equities analysts have recently issued reports on the company. SVB Leerink lifted their price target on Gilead Sciences from $72.00 to $74.00 and gave the company an “outperform” rating in a research note on Friday. Credit Suisse Group raised their price objective on Gilead Sciences from $65.00 to $66.00 and gave the company a “neutral” rating in a report on Friday, February 5th. Guggenheim raised Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Monday, January 4th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday. Finally, Sanford C. Bernstein raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Thursday, April 1st. Ten investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $98.21.

GILD stock opened at $65.80 on Tuesday. The stock has a 50-day moving average price of $65.14 and a 200-day moving average price of $62.74. Gilead Sciences, Inc. has a 1-year low of $56.56 and a 1-year high of $81.76. The company has a current ratio of 3.25, a quick ratio of 3.15 and a debt-to-equity ratio of 1.65. The firm has a market cap of $82.85 billion, a PE ratio of 67.84, a price-to-earnings-growth ratio of 0.67 and a beta of 0.51.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.06 by $0.02. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. On average, analysts forecast that Gilead Sciences, Inc. will post 7.06 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 29th. Stockholders of record on Tuesday, June 15th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 4.32%. The ex-dividend date is Monday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.25%.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

See Also: What are convertible shares? 

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.